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In their analysis in BMC Medicine, Lloyd et al. provide individual patient lifetime risks of prostate cancer diagnosis
and prostate cancer death stratified by ethnicity. This easy to understand information is helpful for men to decide
whether to start prostate-specific antigen testing (i.e. screening). A higher lifetime risk of prostate cancer death in
some ethnic groups is not automatically a license to start screening. The potential benefit in the form of reducing
metastases and death should still be weighed against the potential risk of over diagnosis. In case of ethnicity, this
harm-to-benefit ratio does not differ between groups. Stratifying men for screening based on ethnicity is therefore
not optimal and will not solve the current screening problem. Other methods for risk-stratifying men have been
proven to produce a more optimal harm-to-benefit ratio.
Please see related article: http://www.biomedcentral.com/1741-7015/13/171
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“Prostate cancer is the most common cancer among
men, and the second leading cause of cancer death” is
perhaps the most frequently used first sentence in any
article reporting on prostate cancer today. Although it
sounds a bit like a cliché, the true importance of this
first statement should not be overlooked. The data on
incidence, and especially mortality, were the driving
force for many to search for ways to prevent the occur-
rence of prostate cancer deaths at an early stage. This ul-
timately culminated (at the end of the previous century)
in the start of some of the largest population based
screening studies ever conducted [1, 2]. Now, two
decades after the start of these trials, we know from
the largest trial, the European Randomized study of
Screening for Prostate Cancer (ERSPC, [3]), that we are
able to reduce the number of men that suffer from meta-
static disease by 30 % and men that die of prostate cancer
by roughly 20 % on a population-based level [1, 4, 5]. On
an individual basis, the prostate cancer mortality reduc-
tion can increase up to 51 % when comparing a man
choosing to be regularly screened versus a man not
screened at all [6]. However, this reduction comes at a* Correspondence: m.roobol@erasmusmc.nl
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treatment of prostate cancers that were never destined to
cause complaints let alone kill (indolent prostate cancer)
[1, 7, 8]. On a population-based level, these harms of
prostate cancer screening are judged not to outweigh the
benefits. Much research is therefore currently done into
new markers (e.g. blood, urine, or tissue markers) and
technologies (e.g. MRI) to enable the selective detection
of aggressive prostate cancers and thereby reduce the
harms. However, until truly better markers and technolo-
gies become (widely) available, improving the current
screening strategies by risk-stratifying men into high risk
(and thus potentially a better harm-to-benefit ratio) and
low risk (and thus potentially a poorer harm-to-benefit
ratio) based on currently available data, seems the best
way to go [9]. In addition, instead of offering screening to
the entire population, most major guidelines now advise
to discuss screening on an individual level [10, 11], start-
ing only if individual potential benefits are judged to
weigh against the potential harms of, and by, the indi-
vidual. In this light, Lloyd et al. [12] recently published
in BMC Medicine a manuscript that aimed to provide
individual men with the so needed easy to grasp life-
time risks of prostate cancer diagnosis and prostate
cancer death. They go even further by risk-stratifying
men into high and low risk of prostate cancer death,Access article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
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for some ethnicities as opposed to others. Based on the
presented UK-based data, they hope to help men make
a better informed decision on prostate cancer screen-
ing. However, the question is whether there really is a
true difference between race and prostate cancer mor-
tality that should trigger screening in the one and not
the other, and, if so, is this difference the most optimal
way to risk-stratify men for screening?
Prostate cancer and race
Before discussing these questions in full length, we
would like to start by commending the authors for the
thorough way the data was analyzed and the usefulness
in informing patients of these rather simple looking but
straight forward numbers of life time risk. Of course,
some remarks on these type of analyses are warranted:
ethnicity was missing in some men, errors in linking
major databases could have occurred and, perhaps most
importantly, the currently measured mortality and inci-
dence data are not related in the sense that the mortality
data most likely result from prostate cancer cases diag-
nosed 10 years earlier, a period in which ethnicity ratios
and incidence could have been different. However, over-
all, the authors did a thorough job, including several
sensitivity analyses to look at the effect of imputing dif-
ferent ethnicity rates for the missing data. Generally, the
results represent a “best estimate” of the lifetime risk of
prostate cancer incidence and mortality and, as said, ex-
tremely useful to inform men.
What is of particular interest is the difference in risk
of diagnosis and death per race. Black men are roughly
at twice the risk of diagnosis and death as compared to
white men, who are in turn at roughly twice the risk of
diagnosis and death as compared to Asian men [12].
However, the diagnosis-to-death ratio is very similar
among all ethnicities. In other words, once diagnosed,
there is a one in three chance to die of the disease,
irrespective of race. This finding differs from many
American studies which not only show a higher risk of
diagnosis and death, but also a higher risk of death once
diagnosed (i.e. some races present with proportionally
more aggressive disease) [13]. As suggested by the au-
thors, this could be based on differences in time of diag-
nosis (at a more aggressive stage) and differences in
treatment based on socioeconomical variances instead of
true differences in disease etiology [12]. The reason
(either genetic differences or differences in lifestyle) why
some races do have a higher occurrence of the disease
but once detected do not present with more aggressive
disease is interesting and definitively warrants further re-
search. Nevertheless, this finding already has an import-
ant implication. The authors suggest that black men in
particular should be warned about the risk of prostatecancer death and seek early prostate-specific antigen
(PSA) testing (i.e. screening). Indeed, the double lifetime
risk of dying from prostate cancer for black men would
suggest that the number needed to screen to avoid one
prostate cancer death (often used as a measure of
screening effectiveness, calculated as the reciprocal of
the absolute mortality reduction) would be roughly twice
as low as compared to white men. However, based on
these data, the number of black men that are diagnosed
with a non-lethal prostate cancer will also double. More
men will thus be diagnosed and experience the harms of
over diagnosis and subsequent overtreatment. In fact, if
the lifetime risk of diagnosis and death are both twice as
high, the harm-to-benefit ratio of screening will be un-
changed. If population-based screening is not deemed
ethical on the basis of the currently known harm-to-
benefit ratio, is it then ethical to actively promote
screening in black men who seem to have a similar
harm-to-benefit ratio?
We believe this approach does not adequately address
the current conundrum. We should focus in risk-
stratifying men based on the best harm-to-benefit ratio.
As such, screening should then only be actively offered
if the harm-to-benefit ratio strongly favors the benefits
and should be requested by the individual and discussed
in case of an ambivalent harm-to-benefit ratio, and
avoided in men with no benefit, but mostly harms.
Several methods for achieving this better than average
harm-to-benefit ratio were studied. Based on modelling
data from the ERSPC, limiting screening to specific age
groups (i.e. two to three screens between the ages of 55
and 59 years) was shown to maximize the harm-to-
benefit ratio [14]. Others suggested to start screening at
an even earlier age, stratifying men based on a baseline
PSA value, and only actively offer screening in men
within the highest 10 % of risk of prostate cancer death
[15]. In fact, this strategy was shown to produce a better
risk-to-benefit ratio as compared to stratifying men
based on race or family history of prostate cancer [16].
Once screening starts, optimizing the harm-to-benefit
ratio could be achieved by stratifying men for further,
potentially harmful or burdensome testing (e.g. biopsy
or an MRI). This has been shown possible by using de-
veloped and validated risk calculators [9, 17–19] and is
recommended in guidelines (e.g. European Association
of Urology).
Conclusions
Lifetime risks of prostate cancer diagnosis and prostate
cancer death specified by race provide patients with use-
ful information on their personal condition and can help
in deciding whether to start PSA testing. However, a
higher than average risk of prostate cancer death for
some groups should still be weighed against the harms
Bokhorst and Roobol BMC Medicine  (2015) 13:179 Page 3 of 3of over diagnosis and related overtreatment. Risk stratifi-
cation on the basis of ethnicity results in a comparable
ratio of the harm-to-benefit of prostate cancer screening.
Better methods resulting in a more beneficial harm-to-
benefit ratio are, however, available and should not be
overlooked when considering screening for prostate
cancer.
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